FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series C / Biotech startups that raised Series C in China

Biotech startups that raised Series C in China

Updated 16 Nov 2026

Reset
Biotech startups that raised Series C in China
One-time CSV
  • 160 funded companies, 122 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-c~china-500a.csv160 rows × 18 columns
CompanyCityLast roundAmountDate
QL BiopharmaBeijingSeries C$44.7M2026-09-14
AusperBioHangzhouSeries C$120.0M2026-08-27
Diyingjia TechnologyBeijingSeries C$3.0M2026-07-28
Shengqiang TechnologyShenzhenSeries C$13.7M2026-07-26
Delova BiotechQixiaSeries C$88.6M2026-07-22
Weikaier Pharmaceutical TechnologyNanjingSeries C$29.6M2026-06-02
YolTech TherapeuticsMinhangSeries C$73.8M2026-05-29
ZenitarChengduSeries C$86.0M2026-01-12

8 rows of the CSV in 5 of its 18 columns.

160
Startups
$7.1B
Total raised
28
Funded in the last 12 months
$1.1B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

24 of 160
24 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
QL Biopharma QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. Biotech Beijing Series C $44.7M 2026-09-14 $173.7M Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 101 to 250 2018
AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
Diyingjia Technology Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. Artificial intelligence Beijing Series C $3.0M 2026-07-28 $32.3M IDG Capital, Legend Capital, Microsoft Accelerator 11 to 50 2017
Shengqiang Technology Shengqiang Technology researches, manufactures, and sells high-tech products. Biotech Shenzhen Series C $13.7M 2026-07-26 $13.7M SDIC Venture Capital 101 to 250 2013
Delova Biotech Delova Biotech develops treatments for pain management. Biotech Qixia Series C $88.6M 2026-07-22 $109.8M Legend Capital, Peakview Capital, Hyfinity Investments +1 51 to 100 2017
Weikaier Pharmaceutical Technology Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. Biotech Nanjing Series C $29.6M 2026-06-02 $120.4M SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 501 to 1,000 2010
YolTech Therapeutics YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. Biotech Minhang Series C $73.8M 2026-05-29 $144.9M K2VC, UnityVC, Decheng Capital +1 11 to 50 2021
Zenitar Zenitar conducts drug research and biomedical technology industrialization. Biotech Chengdu Series C $86.0M 2026-01-12 $155.7M Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital 51 to 100 2019
DP Technology DP Technology applies AI to scientific research and industrial R&D challenges worldwide. Artificial intelligence Haidian Series C $113.9M 2025-12-24 $253.7M Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 101 to 250 2018
Darwin Cell Biology Darwin Cell Biology provides cell biotechnology services. Biotech Beijing Series C $27.9M 2025-12-08 $62.4M Shijingshan Modern Innovation Industry Fund, Shanghai Yungu Investment 11 to 50 2016
Healsun Biopharm Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. Biotech Hangzhou Series C $27.8M 2025-11-19 $101.3M Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 251 to 500 2015
GRIT Biotechnology GRIT Biotechnology develops tumor infiltrating lymphocyte immunotherapy for solid tumors. Biotech Shanghai Series C $84.0M 2025-10-14 $153.5M Matrix Partners China, Hillhouse Investment, CICC +2 51 to 100 2019
Yantai Lannacheng Biotechnology Yantai Lannacheng Biotechnology develops Class I diagnostic medications. Biotech Yantai Series C $41.8M 2025-07-20 $103.8M Shenzhen Capital Group, Qianhai Fund of Funds, Yuanhe Capital +1 1 to 10 2021
Tianchen Biotechnology Tianchen Biotechnology develops and sells medical products for ophthalmology. Biotech Tianjin Series C $27.8M 2025-06-03 $41.7M CMB International Capital Corporation 2018
LongBio Pharma LongBio Pharma develops treatments for patients with complement and allergy diseases. Biotech Pudong Series C $28.9M 2025-05-27 $51.1M Oriental Fortune Capital, Shanxi Securities Investment, Hefei Hongda +2 11 to 50 2020
Zhiyi Pharmaceutics Zhiyi Pharmaceutics researches and develops second-generation probiotics and live biotherapeutics. Biotech Guangzhou Series C $13.8M 2024-03-28 Shenzhen Capital Group, SDIC Venture Capital, Sinoking Capital 51 to 100 2013
Hengruiyuan Hengruiyuan develops immune cell-based medications for treating solid tumors. Biotech Songjiang Series C $14.1M 2024-01-09 $42.8M Haiyuan Capital, Zhongke Kechuang 501 to 1,000 2015
DIAGENS DIAGENS is a Hangzhou-based biotechnology firm that provides in-vitro diagnostic products and medical equipment. Biotech Hangzhou Series C $14.1M 2023-12-29 Shenzhen Guozhong Venture Capital Management, Haiyuan Capital, China Venture Capital HRVC +2 51 to 100 2014
Qitan Technology Qitan Technology develops genome sequencing technology. Biotech Chengdu Series C $14.1M 2023-12-28 Hillhouse Investment, Gaorong Capital, CDH Investments +1 51 to 100 2016
Zenshine Pharma Zenshine Pharma develops small molecule drugs for cancer and autoimmune diseases. Biotech Nanjing Series C $13.7M 2023-10-13 $28.7M Matrix Partners China, Cybernaut Venture Capital, Kunlun Capital +2 11 to 50 2018
LYNK Pharmaceuticals LYNK Pharmaceuticals is a biotech company that discovers and develops new medicines. Biotech Hangzhou Series C $16.7M 2023-09-21 Legend Capital, Kaitai Capital, New Alliance Capital +2 11 to 50 2018
Canton Biologics Canton Biologics provides biologics contract development and manufacturing outsourcing services. Biotech Guangzhou Series C $41.3M 2023-09-13 $41.7M SDIC Venture Capital, Rongtuo Capital Management, Taipu Life Sciences Investment 101 to 250 2016
Konfoong Biotech International Konfoong Biotech International is a biotechnology company. Artificial intelligence Ningbo Series C $14.9M 2022-07-12 Intel Capital, Yinxinggu Capital 101 to 250 2011
MegaRobo Unicorn MegaRobo is an AI and robotics company serving life sciences, clinical diagnosis, and applied chemistry. Artificial intelligence Beijing Series C $300.0M 2022-06-15 Innoangel Fund, Pavilion Capital 1,001 to 5,000 2016

Table 1. Biotech startups that raised Series C in China: the 24 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 160.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
2 DP Technology DP Technology applies AI to scientific research and industrial R&D challenges worldwide. Artificial intelligence Haidian Series C $113.9M 2025-12-24 $253.7M Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 101 to 250 2018
3 Delova Biotech Delova Biotech develops treatments for pain management. Biotech Qixia Series C $88.6M 2026-07-22 $109.8M Legend Capital, Peakview Capital, Hyfinity Investments +1 51 to 100 2017
4 Zenitar Zenitar conducts drug research and biomedical technology industrialization. Biotech Chengdu Series C $86.0M 2026-01-12 $155.7M Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital 51 to 100 2019
5 YolTech Therapeutics YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. Biotech Minhang Series C $73.8M 2026-05-29 $144.9M K2VC, UnityVC, Decheng Capital +1 11 to 50 2021
6 QL Biopharma QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. Biotech Beijing Series C $44.7M 2026-09-14 $173.7M Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 101 to 250 2018
7 Weikaier Pharmaceutical Technology Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. Biotech Nanjing Series C $29.6M 2026-06-02 $120.4M SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 501 to 1,000 2010
8 Darwin Cell Biology Darwin Cell Biology provides cell biotechnology services. Biotech Beijing Series C $27.9M 2025-12-08 $62.4M Shijingshan Modern Innovation Industry Fund, Shanghai Yungu Investment 11 to 50 2016
9 Healsun Biopharm Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. Biotech Hangzhou Series C $27.8M 2025-11-19 $101.3M Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 251 to 500 2015
10 Shengqiang Technology Shengqiang Technology researches, manufactures, and sells high-tech products. Biotech Shenzhen Series C $13.7M 2026-07-26 $13.7M SDIC Venture Capital 101 to 250 2013

Table 2. Biotech startups that raised Series C in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Legend Capital Venture capital firm Beijing, China 4 2% 2 Diyingjia Technology, Delova Biotech
2 SDIC Venture Capital Venture capital firm Xicheng, China 4 2% 2 Shengqiang Technology, Weikaier Pharmaceutical Technology
3 Matrix Partners China Venture capital firm Beijing, China 4 2% 1 DP Technology
4 Decheng Capital Venture capital firm Menlo Park, United States 3 2% 1 YolTech Therapeutics
5 Hillhouse Investment Angel group Singapore 3 2% 1 DP Technology
6 Qianhai Fund of Funds Private equity firm Shanzhen, China 3 2%
7 Oriental Fortune Capital Venture capital firm Shenzhen, China 3 2%
8 Shenzhen Guozhong Venture Capital Management Venture capital firm Shenzhen, China 3 2%
9 Qiming Venture Partners Venture capital firm Shanghai, China 2 1% 2 AusperBio, DP Technology
10 Hankang Capital Venture capital firm Shanghai, China 2 1% 1 AusperBio
11 China Life Private Equity Investment Private equity firm Beijing, China 2 1% 1 Weikaier Pharmaceutical Technology
12 Grand Flight Investment Private equity firm Shanghai, China 2 1% 1 YolTech Therapeutics
13 Shanghai Biomedical Industrial Equity Investment Fund Venture capital firm Huangpu, China 2 1% 1 Healsun Biopharm
14 Yinxinggu Capital Venture capital firm Hangzhou, China 2 1% 1 Healsun Biopharm
15 Shenzhen Capital Group Venture capital firm Nanshan, China 2 1%

Table 3. Biotech startups that raised Series C in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 142 89% $6.5B
Software 6 4% $413.9M
Artificial intelligence 5 3% $313.9M
Hardware 4 2%
Cybersecurity 1 1%

Table 4. Biotech startups that raised Series C in China by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series C 160 100% $29.9M

Table 5. Biotech startups that raised Series C in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 29 18%
Hangzhou 20 12%
Beijing 19 12%
Nanjing 15 9%
Guangzhou 12 8%
Shenzhen 10 6%
Suzhou 10 6%
Haidian 5 3%
Wuhan 4 2%
Minhang 4 2%
Changping 3 2%
Tianjin 3 2%

Table 6. Biotech startups that raised Series C in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
September 2026 2 7% $84.7M
August 2026 3 11% $157.1M
July 2026 7 25% $234.2M
June 2026 3 11% $73.8M
May 2026 2 7% $123.8M
April 2026 2 7% $101.7M
March 2026 1 4% $14.5M
February 2026 2 7% $65.0M
January 2026 1 4% $86.0M
December 2025 4 14% $156.0M
November 2025 1 4% $27.8M

Table 7. Biotech startups that raised Series C in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 23 14% $941.0M
2025 24 15% $725.7M
2024 17 11% $134.1M
2023 19 12% $311.3M
2022 20 12% $731.4M
2021 25 16% $1.9B

Table 8. Biotech startups that raised Series C in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2020 to 2022 8 5%
2015 to 2019 80 50%
2010 to 2014 42 26%
Before 2010 30 19%

Table 9. Biotech startups that raised Series C in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 12 8%
11 to 50 28 19%
51 to 100 41 27%
101 to 250 34 23%
251 to 500 14 9%
501 to 1,000 17 11%
1,001 to 5,000 4 3%
5,001 to 10,000 1 1%

Table 10. Biotech startups that raised Series C in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in China whose last round is Series C are on the list?
160, in the file dated 16 November 2026. 28 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 160 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series C in China: 160 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in China

Other sectors that raised Series C in China

Cite: FundingWatcher, 160 biotech companies in China whose most recent round is Series C, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-c/china-500a/